To access this element change to forms mode OFF
Grant Award View - GA217932
4CAST: A phase I/II study evaluating the safety and efficacy of VT-464...
GA ID:
GA217932
Agency:
Department of Health and Aged Care
Approval Date:
4-Nov-2021
Publish Date:
16-Feb-2022
Category:
Health and Medical Research
Grant Term:
1-Jan-2022 to 31-Dec-2024
Value (AUD):
$668,444.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 21/22 1.1 Health Policy Research and Analysis
Grant Program:
MRFF Research Grants
Grant Activity:
4CAST: A phase I/II study evaluating the safety and efficacy of VT-464 in combination with chemotherapy in patients with metastatic breast cancer
Purpose:
With no curative therapies for patients with treatment refractory triple-negative breast cancer, there is an urgent need to develop new therapeutic strategies to improve survival outcomes. We discovered that blocking the androgen receptor prevents and treats chemotherapy-resistant triple-negative breast cancer. When combined with chemotherapy, overall survival is significantly improved in pre-clinical models. We have now developed a clinical trial to test this new therapy in the clinic.
GO ID:
GO Title:
MRFF 2021 Rare Cancers Rare Diseases Unmet Need General - Grant Opportunity
Internal Reference ID:
2021/MRF2014663
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of New South Wales
Recipient ABN:
57 195 873 179
Grant Recipient Location
Suburb:
Sydney
Town/City:
Sydney
Postcode:
2052
State/Territory:
NSW
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW
Postcode:
Country:
AUSTRALIA